A team led by UCL researchers with Great Ormond Street Hospital (GOSH) and Moorfields Eye Hospital, found B cells-alongside T cells-play a key role in arthritis-related eye disease (JIA uveitis), a condition that can cause long-term vision loss in children.
The study, funded by the Medical Research Foundation, Moorfields Eye Charity, Arthritis UK and Fight for Sight challenges how the disease has been previously understood, and could open the door to new treatments that help protect children’s sight.
Juvenile idiopathic arthritis (JIA) is the most common form of arthritis in children under the age of 16, affecting around one in every 1,000 children in the UK. Approximately 30% of patients with JIA also develop uveitis - an inflammatory condition of the eye that is potentially sight-threatening.
Although some treatments are available today for the condition, up to a third of affected children still experience some degree of permanent vision loss by the time they reach adulthood.
A team from UCL, GOSH, and Moorfields Eye Hospital published a new study today in Nature Communications that provides a clearer picture of the immune cells involved in JIA-associated uveitis.
"JIA-uveitis can be difficult to detect early, because in some patients, it can cause no obvious symptoms," explains Dr Bethany Jebson (Research Fellow at UCL), first author of the study.
Within the immune system, B and T cells are crucial white blood cells that protect the body against specific pathogens, each playing distinct roles in providing resistance against infections and toxins. As an autoimmune condition, JIA-uveitis occurs when the immune system mistakenly attacks tissues in the eye.
To date, T cells have been considered the primary drivers of the disease’s autoimmune response and subsequent tissue damage. However, this new data suggests that B cells are also playing a role in the disease - presenting a new potential treatment target.
However, studying the disease effectively and understanding the immune responses that cause eye inflammation requires careful analysis of eye samples from children, which are difficult to safely obtain. This has affected how researchers have been able to study the disease - until now.
Senior author of the study, Dr Elizabeth Rosser (Lizzy, Associate Professor at UCL), explains , "Through immense collaborative effort with Great Ormond Street Hospital and Moorfields Eye Hospital, we examined rare samples taken directly from the eyes of children with uveitis, who were already undergoing surgery for related complications such as cataracts. We also were able to investigate carefully preserved historical eye samples."
In this study, the team combined blood data with these rare eye samples to explore disease mechanisms more directly. They first compared blood samples from children with arthritis alone (JIA) and children with both arthritis and eye inflammation (JIA-uveitis). They then identified and counted various types of immune cells in the eyes of patients.
"This allowed us to see which immune cells were present in the inflamed eye and compare this with what we saw in the blood," adds Dr Rosser.
The researchers observed that B cells were consistently present in increased numbers in the blood and inflamed eyes of JIA-uveitis patients.
Fundamentally, this highlights the pivotal role of B cells as additional drivers in the disease pathology of JIA-uveitis. "Our findings challenge the idea that uveitis is driven by T cells alone and show that B cells may also be playing an important role," says Dr Jebson.
Moreover, in a mouse model of uveitis, the researchers found that blocking communication between the two immune cell types led to reduced eye inflammation.
"While results from animal studies cannot be directly applied to children, they can help identify immune pathways that may be important in disease," adds Dr Rosser.
Dr Ameenat Lola Solebo (Wellcome Trust Career Development Fellow and Consultant Paediatric Ophthalmologist at GOSH), another author of the study, comments, "This work is a great example of the power of patient-driven research. It uses samples from a new biobank (called ’CHOIR’) which was inspired by and named by our patients."
The findings mark a major shift in how the disease process of uveitis is understood, shedding light on key mechanisms that lead to vision loss in children with the condition.
Dr Rosser adds, "The pathway targeted in this study is already being explored in adults with autoimmune diseases. Following careful clinical trials, we hope that existing treatments could one day be adapted or tested for this sight-threatening condition.
"Our next steps are to understand if we can find similar pathways at play in children with eye disease who do not have arthritis, as this group is underrepresented in research studies."
Angela Hind, Chief Executive at the Medical Research Foundation, comments, "For reasons we still don’t fully understand, children with arthritis can also develop uveitis, and for many the disease does not respond to current treatments, with devastating consequences for their sight and long-term health.
This research has uncovered vital new insights into the immune responses driving eye inflammation, highlighting the importance of medical research in improving outcomes for children with serious and potentially blinding eye diseases. We hope these findings will lay the groundwork for future research and more effective treatments."
Key points about the study:
In JIA, many patients also develop uveitis (JIA-uveitis), risking life-long vision loss. The mechanisms driving this remain understudied.
Here, the authors identify elevated DN1 B cells in JIA-uveitis and show that targeting B-T cell interactions suppresses disease in a mouse model of uveitis.
These findings support a conceptual shift that uveitis is primarily a T-cell driven disease and provide evidence for potential new therapies that also consider B cells as drivers in disease development.
Paper: Altered B cell activation contributes to the immunopathogenesis of childhood arthritis-associated uveitis
University College London, Gower Street, London, WC1E 6BT (0) 20 7679 2000
